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Comparison of SP142 and 22C3
Immunohistochemistry PD-L1 Assays for Clinical
Efficacy of Atezolizumab in Non–Small Cell Lung
Cancer: Results From the Randomized OAK Trial
Shirish Gadgeel,1 Fred R. Hirsch,2 Keith Kerr,3 Fabrice Barlesi,4 Keunchil Park,5
Achim Rittmeyer,6 Wei Zou,7 Namrata Bhatia,7 Hartmut Koeppen,7
Sarah M. Paul,7 David Shames,7 Jing Yi,7 Christina Matheny,7 Marcus Ballinger,7
Mark McCleland,7 David R. Gandara8
Abstract
It is unclear whether PD-L1 assays differ in their ability to predict clinical outcomes with checkpoint
immunotherapy. This OAK analysis indicated greater survival with atezolizumab than docetaxel regardless
of the assay used to determine tumor PD-L1 status (SP142 or 22C3) in a second-/third-line metastatic NSCLC
population. The SP142 and 22C3 assays similarly predict atezolizumab efﬁcacy at validated PD-L1 thresholds.
Background: This phase III OAK trial (NCT02008227) subgroup analysis (data cutoff, January 9, 2019) evaluated the
predictive value of 2 PD-L1 IHC tests (VENTANA SP142 and Dako 22C3) for beneﬁt from atezolizumab versus docetaxel
by programmed death ligand 1 (PD-L1) status in patients with previously treated metastatic non–small cell lung cancer.
Methods: PD-L1 expression was assessed prospectively with SP142 on tumor cells (TC) and tumor-inﬁltrating immune
cells (IC) and retrospectively with 22C3 using a tumor proportion score (TPS) based on TC membrane staining. Efﬁcacy
was assessed in the 22C3 biomarker-evaluable population (22C3-BEP) (n = 577; 47.1% of SP142-intention-to-treat
population) and non–22C3-BEP (n = 648) in PD-L1 subgroups (high, low, and negative) and according to selection
by 1 or both assays. Results: In the 22C3-BEP, overall survival beneﬁts with atezolizumab versus docetaxel were
observed across PD-L1 subgroups; beneﬁts were greatest in SP142-deﬁned PD-L1–high (TC3 or IC3: hazard ratio
[HR], 0.39 [95% conﬁdence interval (CI), 0.25-0.63]) and 22C3-deﬁned PD-L1–high (TPS ≥ 50%: HR, 0.56 [95% CI,
0.38-0.82]) and low (TPS, 1% to < 50%: HR, 0.55 [95% CI, 0.37-0.82]) groups. Progression-free survival improved
with increasing PD-L1 expression for both assays. SP142 and 22C3 assays identiﬁed overlapping and unique patient
populations in PD-L1–high, positive, and negative subgroups. Overall survival and progression-free survival beneﬁts

Abbreviations: CI, confidence interval; HR, hazard ratio; IC, tumor-infiltrating immune cells; IHC, immunohistochemistry; ITT, intention to treat; NSCLC, non–small cell lung
cancer; OS, overall survival; PD-1, programmed death 1; PD-L1, programmed death ligand 1; PFS, progression-free survival; TC, tumor cells; TPS, tumor proportion score.
1

Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA
Icahn School of Medicine, Mount Sinai, NY, USA
3
Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, Scotland
4
Aix Marseille Universite, Assistance Publique Hôpitaux de Marseille, Marseille, France
5
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
6
Lungenfachklinik Immenhausen, Immenhausen, Germany
7
Genentech Inc, South San Francisco, CA, USA
8
UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
2

Submitted: Mar 3, 2021; Revised: May 21, 2021; Accepted: May 21, 2021; Epub: 30 May 2021
Address for correspondence: Shirish Gadgeel, MD, Henry Ford Cancer Institute/Henry Ford Health System, 2800 W Grand Blvd, Detroit, MI 48202 USA
E-mail contact: sgadgee1@hfhs.org

1525-7304/$ - see front matter © 2021 The Authors. Published by Elsevier Inc.
This
is
an
open
access
article
under
the
CC
BY
license
(http://creativecommons.org/licenses/by/4.0/)
https://doi.org/10.1016/j.cllc.2021.05.007

Clinical Lung Cancer January 2022

21

Comparison of Immunohistochemistry PD-L1 Assays
favored atezolizumab over docetaxel in double PD-L1–positive and negative groups; patients with both SP142- and
22C3-positive tumors derived the greatest beneﬁt. Conclusions: Despite different scoring algorithms and differing
sensitivity levels, the SP142 and 22C3 assays similarly predicted atezolizumab beneﬁt at validated PD-L1 thresholds
in patients with non–small cell lung cancer.
Clinical Lung Cancer, Vol. 23, No. 1, 21–33 © 2021 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Keywords: Programmed death ligand 1, Inter-assay concordance, Progression-free survival, Overall survival,
Biomarker-evaluable population

Introduction
Docetaxel was a long-standing standard of care for the secondor third-line treatment of advanced non–small cell lung cancer
(NSCLC) based on improved overall survival (OS) in controlled
phase III studies.1-3 The introduction of checkpoint inhibitors
targeting the programmed death ligand 1 (PD-L1)/programmed
death 1 (PD-1) pathway has dramatically altered the management
of NSCLC, with shown OS benefits in patients with advanced
disease, both in first and subsequent lines of therapy.4 The immune
checkpoint protein PD-L1 is expressed on tumor cells (TC) and
tumor-infiltrating immune cells (IC) and can facilitate suppression of anticancer immune mechanisms by binding to the PD-1
and B7.1 receptors.5-7 The humanized engineered IgG1 monoclonal
antibody atezolizumab blocks the binding of PD-L1 to its receptors
PD-1 and B7.1, thus restoring tumor-specific immunity.6 , 8
The phase III OAK trial in a population of patients receiving second- or third-line treatment for NSCLC showed improved
survival with atezolizumab versus docetaxel regardless of PD-L1
expression on TC or IC, as identified using the VENTANA
PD-L1 SP142 immunohistochemistry (IHC) assay.9 , 10 Among
patients with advanced NSCLC, atezolizumab improved median
OS compared with docetaxel, both in the primary analysis based
on the first 850 patients enrolled (intention-to-treat [ITT] population; data cutoff, July 7, 2016: hazard ratio [HR], 0.73 [95%
confidence interval (CI), 0.62-0.87]; P = .0003) and in the final
analysis of 1225 patients (SP142-ITT1225; data cutoff, January
9, 2019: HR, 0.78 [95% CI, 0.68-0.89]; P < .0001).9-11 In the
OAK study, OS favored atezolizumab over docetaxel across PDL1–positive subgroups, with patients who had PD-L1–high tumors
(TC3 or IC3) deriving the greatest OS benefit (HR, 0.41 [95% CI,
0.27-0.64]).10 OS improvement with atezolizumab versus docetaxel
was also shown in patients with PD-L1–negative tumors (TC0 and
IC0) (HR, 0.75 [95% CI, 0.59-0.96]).10 Based on these findings,
atezolizumab has been approved as a second- or later-line treatment
for patients with metastatic NSCLC.12
Multiple PD-L1 IHC assays incorporating alternative antibody
clones (eg, SP263, 22C3, and 28-8) and scoring criteria different from those of the SP142 assay have been clinically validated
as companion diagnostics for PD-L1/PD-1 inhibitors.13-15 For
NSCLC, the SP263, 22C3, and 28-8 assays are used to measure
PD-L1 expression specifically on TC, as opposed to the SP142
assay, which measures PD-L1 expression on both TC and IC.
Notably, for other tumor types, the 22C3 assay has been modified
to include both TC and IC measurement in a combined positive
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score.16-20 Numerous analytical comparisons of these assays have
been performed in efforts to harmonize the NSCLC PD-L1 testing
landscape, and results from key studies, such as the Blueprint PDL1 IHC Assay Comparison Project, suggest that the TC-based assays
generally show high analytical concordance, whereas SP142 was less
sensitive for both TC and IC staining.21-24 However, the comparative clinical sensitivity of IHC assays at validated PD-L1 cutoffs
has not been extensively investigated in patients with NSCLC after
treatment.
The aim of the study was to evaluate the predictive value of 2 PDL1 IHC tests for benefit from atezolizumab therapy in patients with
metastatic NSCLC treated with atezolizumab or docetaxel from the
OAK trial, in particular the VENTANA SP142 and Dako 22C3
IHC assays, which have different characteristics with respect to TC
and IC staining.

Materials and Methods
Patients and Treatment
OAK was a randomized, open-label, international, phase III study
assessing the efficacy and safety of atezolizumab versus docetaxel in
1225 patients with metastatic NSCLC (NCT02008227). Detailed
patient eligibility criteria and study methodology have been
described previously for the primary and final analyses.9-11 Briefly,
eligible adult patients had squamous or nonsquamous NSCLC,
measurable disease per Response Evaluation Criteria in Solid
Tumors and an Eastern Cooperative Oncology Group performance
status of 0 or 1.
Patients were randomly assigned (1:1) to receive either
atezolizumab 1200 mg or docetaxel 75 mg/m2 intravenously every 3
weeks until loss of clinical benefit or disease progression, as assessed
by the investigator. Continuation of atezolizumab treatment beyond
disease progression was permitted if the patient was judged by the
investigator to be deriving clinical benefit. Crossover from docetaxel
to atezolizumab was only allowed after the primary analysis revealed
benefit with atezolizumab.9 , 10 The primary endpoint of the study
was OS in the ITT population and the PD-L1–positive subgroup
(≥ 1% PD-L1 expression [TC1/2/3 or IC1/2/3]).10
The study protocol was reviewed and approved by the independent ethics committees of the 208 participating sites and was
conducted in accordance with the guidelines for Good Clinical
Practice and the Declaration of Helsinki. Written informed consent
was provided by all patients.
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Immunohistochemistry Assays
Archival or fresh tumor samples (blocks or formalin-fixed
paraffin-embedded slides) were prospectively centrally assessed at
HistoGeneX laboratories (Antwerp, Belgium, and Naperville, IL)
for PD-L1 expression using the VENTANA SP142 PD-L1 IHC
assay (Ventana Medical Systems Inc). In addition, 22C3 staining
was performed retrospectively using the Dako pharmDx 22C3 IHC
assay (Dako North America Inc) on freshly cut tissue sections or
tissue sections < 6 months old that were stored under appropriate
conditions.25 , 26
Published scoring criteria for the SP142 assay were used to assess
TC expressing PD-L1 as a percentage of total TC and IC expressing
PD-L1 as a percentage of tumor area: (1) PD-L1 positive: TC or IC
≥ 1% (TC1/2/3 or IC1/2/3); (2) PD-L1 low: TC or IC ≥ 1% and
TC < 50% and IC < 10% (TC1/2 or IC1/2); (3) PD-L1 high: TC
≥ 50% or IC ≥ 10% (TC3 or IC3, respectively); and (4) PD-L1
negative: TC and IC < 1% (TC0 and IC0, respectively).27 For the
22C3 assay, PD-L1 status was defined by tumor proportion score
(TPS) cutoff values: (1) PD-L1 positive: TPS ≥ 1%; (2) PD-L1
low: TPS of 1% to < 50%; (3) PD-L1 high: TPS ≥ 50%; and (4)
PD-L1 negative: TPS < 1%.26

Statistical Analysis
Analyses were performed in the 22C3 biomarker-evaluable
population (22C3-BEP) (comprising patients with available
formalin-fixed paraffin-embedded tumor tissue slides that were
sectioned within the 6-month cut slide–stability staining window26 )
and non–22C3-BEP. Kaplan-Meier estimates and corresponding
medians for survival outcomes were calculated for the 22C3-BEP
and SP142-ITT populations and for each assay at the predefined
PD-L1 cutoff values and according to selection using both assays
(patients with tumors that were double positive, double negative,
and uniquely positive by both assays). Efficacy was assessed by
each assay independently within the 22C3-BEP and also within the
overlapping and uniquely identified patient populations. Because
subgroup analyses were exploratory in nature and might potentially comprise small sample populations, HRs and 95% CIs were
derived from unstratified and unadjusted Cox models in comparisons of investigator-assessed progression-free survival (PFS) and OS
within evaluable populations and PD-L1 subgroups. Concordance
between SP142- and 22C3-defined PD-L1 subgroups was visualized
and presented descriptively using Venn diagrams.

Results
Characteristics of the OAK SP142-ITT and Biomarker
Populations
Overall, 1225 patients were included in the SP142-ITT population based on a data cutoff date of January 9, 2019. Of these,
577 patients (atezolizumab, 295; docetaxel, 282), or 47.1%, of the
SP142-ITT population made up the 22C3-BEP according to the
availability of tumor samples within the 6-month cut slide–stability
window for 22C3 analysis. The remaining 648 patients made up the
non–22C3-BEP (atezolizumab, 318; docetaxel, 330). Baseline clinical and demographic characteristics were generally balanced between
the treatment arms in the SP142-ITT and 22C3-BEP (Table 1). The
proportions of Asian patients were markedly lower in the 22C3-

BEP (atezolizumab, 3.4%; docetaxel, 5.7%) than in either the non–
22C3-BEP (35.9% and 33.0%, respectively) or overall SP142-ITT
population (20.2% and 20.4%, respectively), but the distribution
was balanced between arms. Additionally, in the non–22C3-BEP,
we observed numerically higher frequencies of EGFR mutations
in both arms and lower baseline sum of longest diameters in the
docetaxel arm relative to those in the SP142-ITT and 22C3-BEP.
When defined by the SP142 assay, prevalence rates for PD-L1–
positive (TC1/2/3 or IC1/2/3) subgroups were similar between the
SP142-ITT population (56%)11 and 22C3-BEP (62%) (Table 2).
Negative PD-L1 expression (SP142 TC0 and IC0) was observed in
43% and 37% of tumors in the SP142-ITT population and 22C3BEP, respectively. Prevalence rates for 22C3-defined PD-L1–positive
groups according to TPS ≥ 1% or ≥ 50% were 47% and 24%,
respectively, whereas 53% of patients had PD-L1–negative (TPS <
1%) tumors (Table 2).

Outcomes in the SP142-ITT and 22C3-BEP
At the data cutoff (January 9, 2019), the median follow-up was
47.7 months in the SP142-ITT population.11 Survival analyses
for atezolizumab versus docetaxel in the 22C3-BEP are shown in
Figure 1 and Supplemental Figure S1. In general, survival benefits
with atezolizumab relative to docetaxel were similar in the SP142ITT population11 and the 22C3-BEP for both OS (median OS,
12.3 vs. 8.2 months; HR, 0.65 [95% CI, 0.54-0.78]) and PFS
(median PFS, 2.8 vs. 3.1 months; HR, 0.80 [95% CI, 0.67-0.95]).
Less favorable benefit was observed in the non–22C3-BEP for OS
(median OS, 13.8 vs. 12.4 months; HR, 0.90 [95% CI, 0.76-1.07])
and PFS (median PFS, 2.7 vs. 4.2 months; HR, 1.13 [95% CI,
0.96-1.32]) than in the BEP and ITT populations.11
Overall response rates (ORRs) with atezolizumab and docetaxel
were 16% and 9%, respectively, in the 22C3-BEP (difference in
ORR between atezolizumab and docetaxel [ORR], 7% [95%
CI, 1%-12%]); 13% and 15%, respectively, in the non–22C3-BEP
(ORR, −2% [95% CI, −8% to 3%]); and 14% and 12%,
respectively, in the SP142-ITT (ORR, 2% [95% CI, −2% to
6%]) populations (Figure 3).

Outcomes by Assay-Defined PD-L1 Subgroups
There were OS benefits with atezolizumab versus docetaxel across
PD-L1 subgroups (positive, high, low, and negative expression)
regardless of IHC assay in the 22C3-BEP (Figures 1A and 2). OS
benefits were greatest in the group with the highest PD-L1 expression defined by the SP142 assay (TC3 or IC3: HR, 0.39 [95%
CI, 0.25-0.63]) and high and low PD-L1 expression defined by the
22C3 assay (TPS ≥ 50%: HR, 0.56 [95% CI, 0.38-0.82]; TPS,
1% to < 50%: HR, 0.55 [95% CI, 0.37-0.82]). The HR point
estimates for OS were higher for atezolizumab versus docetaxel in
the SP142-defined PD-L1–low expression group (TC1/2 or IC1/2:
HR, 0.80 [95% CI, 0.60-1.05]) and all PD-L1–negative subgroups
(SP142 TC0 and IC0: HR, 0.66 [95% CI, 0.49-0.89]; 22C3 TPS
< 1%: HR, 0.75 [95% CI, 0.59-0.97]). Similar trends for OS were
observed across PD-L1 subgroups in the SP142-ITT population.11
PFS in the atezolizumab and docetaxel groups according to assaydefined PD-L1 expression are shown in Figure 1B and Supplemental
Figure S2. Atezolizumab was associated with increasing PFS efficacy
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Table 1

Baseline Demographics and Characteristics

Characteristic

Median age (range), years

Atezolizumab

Docetaxel

SP142-ITT
(n = 613)

22C3-BEP
(n = 295)

Non–22C3BEP
(n = 318)

SP142-ITT
(n = 612)

22C3-BEP
(n = 282)

Non–22C3BEP
(n = 330)

63
(25-84)

63
(25-82)

63
(33-84)

63
(34-85)

64
(34-85)

63
(34-85)

Sex, n (%)
Male

379 (61.8)

185 (62.7)

194 (61)

379 (61.9)

175 (62.1)

204 (61.8)

Female

234 (38.2)

110 (37.3)

124 (39)

233 (38.1)

107 (37.9)

126 (38.2)

White

438 (71.5)

253 (85.8)

185 (58.2)

432 (70.6)

235 (83.3)

197 (59.7)

Asian

124 (20.2)

10 (3.4)

114 (35.9)

125 (20.4)

16 (5.7)

109 (33)

Othera

51 (8.3)

32 (10.9)

19 (6)

55 (9)

31 (11)

24 (7.3)

121 (19.7)

7 (2.4)

114 (35.9)

112 (18.3)

6 (2.1)

106 (32.1)

14 (2.3)

5 (1.7)

9 (2.8)

15 (2.5)

5 (1.8)

10 (3)

Europe

318 (51.9)

172 (58.3)

146 (45.9)

300 (49)

153 (54.3)

147 (44.6)

North America

160 (26.1)

111 (37.6)

49 (15.4)

185 (30.2)

118 (41.8)

67 (20.3)

0

221 (36.1)

110 (37.3)

111 (34.9)

234 (38.2)

98 (34.8)

136 (41.2)

1

392 (64)

185 (62.7)

207 (65.1)

378 (61.8)

184 (65.3)

194 (58.8)

Race, n (%)

Region, n (%)
Asia-Paciﬁc
Central/South America

ECOG PS, n (%)

History of tobacco use, n (%)
Never

112 (18.3)

51 (17.3)

61 (19.2)

96 (15.7)

33 (11.7)

63 (19.1)

Current or previous

501 (81.7)

244 (82.7)

257 (80.8)

516 (84.3)

249 (88.3)

267 (80.9)

Nonsquamous

452 (73.7)

207 (70.2)

245 (77)

452 (73.9)

192 (68.1)

260 (78.8)

Squamous

161 (26.3)

88 (29.8)

73 (23)

160 (26.1)

90 (31.9)

70 (21.2)

No

487 (79.5)

230 (78)

257 (80.8)

497 (79.6)

219 (77.7)

268 (81.2)

Yes

126 (20.6)

65 (22)

61 (19.2)

125 (20.4)

63 (22.3)

62 (18.8)

2.9

3

2.9

2.9

3.1

2.8

70
(10-316)

69
(10-309)

71
(10-316)

66
(10-314)

72.5
(10-240)

60
(11-314)

Histology type, n (%)

Liver metastases

Metastatic sites, mean
SLD, median (range), mm
EGFR mutation, n (%)
Positive

60 (9.8)

20 (6.8)

40 (12.6)

53 (8.7)

19 (6.7)

34 (10.3)

Negative

455 (74.2)

218 (73.9)

237 (74.5)

464 (75.8)

207 (73.4)

257 (77.9)

Unknown

98 (16)

57 (19.3)

41 (12.9)

95 (15.5)

56 (19.9)

39 (11.8)

EML4-ALK translocation, n (%)
Positive

4 (0.7)

2 (0.7)

2 (0.6)

1 (0.2)

0 (0)

1 (0.3)

Negative

315 (51.4)

130 (44.1)

185 (58.2)

288 (47.1)

124 (44)

164 (49.7)

Unknown

294 (48)

163 (55.3)

131 (41.2)

323 (52.8)

158 (56)

165 (50)

Abbreviations: BEP = biomarker-evaluable population; ECOG = Eastern Cooperative Oncology Group performance status; SLD = sum of longest diameters.
a
Other includes American Indian, Alaska Native, African American, black, Hawaiian Native, other Paciﬁc Islander, other, multiple, and unknown.

with increasing PD-L1 expression when defined by the SP142 assay
within the 22C3-BEP, with the greatest improvement observed at
the highest cutoff (TC1/2 or IC1/2: HR, 0.82 [95% CI, 0.641.06]; TC1/2/3 or IC1/2/3: HR, 0.73 [95% CI, 0.58-0.91]; TC3 or
IC3: HR, 0.50 [95% CI, 0.32-0.80]). A similar trend was observed
in PD-L1 subgroups within the SP142-ITT population. Increasing PFS efficacy was also observed across 22C3-defined PD-L1
subgroups, with the greatest improvement observed at the highest
cutoff (TPS, 1% to < 50%: HR, 0.77 [95% CI, 0.53-1.12]; TPS
≥ 1%: HR, 0.62 [95% CI, 0.47-0.80]; TPS ≥ 50%: HR, 0.52

24

Clinical Lung Cancer January 2022

[95% CI, 0.36-0.76]). No PFS improvement with atezolizumab
was observed in the PD-L1–negative subgroup defined by SP142
or 22C3.
In the 22C3-BEP, ORRs with atezolizumab ranged from 9% to
27% among SP142-defined PD-L1 subgroups (TC0 and IC0 to
TC3 or IC3) and from 10% to 26% across 22C3-defined PDL1 subgroups (TPS < 1% to TPS ≥ 50%) (Figure 3). Among
the 22C3-BEP, ORRs with docetaxel were similar across 22C3defined PD-L1 subgroups (9% for all groups) and showed variation in PD-L1 subgroups defined by the SP142 assay (4%-14%).

Shirish Gadgeel et al
Table 2

PD-L1 Prevalence Within the 22C3-BEP
Assay-Defined PD-L1 Subgroup, n (%)

22C3-BEP (n = 577)a

SP142
TC0 and IC0

215 (37.3)

TC1/2 or IC1/2

266 (46.3)

TC1/2/3 or IC1/2/3

360 (62.4)

TC3 or IC3

94 (16.3)

22C3
TPS < 1%
TPS 1% to ˂ 50%

306 (53)
133 (23.1)

TPS ≥ 1%

271 (47)

TPS ≥ 50%

138 (23.9)

Abbreviations: 22C3-BEP = biomarker-evaluable population; IC = tumor-inﬁltrating immune cells;
ITT = intention to treat; PD-L1 = programmed death ligand 1; TC = tumor cells; TPS = tumor
proportion score.
a
Analysis of PD-L1 prevalence in the TC1/2 or IC1/2 subgroup was based on an evaluable population
of 575 patients.

Overall, ORRs were increased with atezolizumab versus docetaxel
across PD-L1–negative (TC0 and IC0: ORR, 3% [95% CI,
−4% to 11%]), PD-L1–low (TC1/2 or IC1/2: ORR, 3% [95%
CI, −6% to 13%]), and PD-L1–high (TC3 or IC3: ORR, 22%
[95% CI, 6%-38%]) groups according to the SP142 assay in the
22C3-BEP. ORRs were also greater with atezolizumab than with
docetaxel in 22C3-defined PD-L1–negative (TPS < 1%: ORR,
1% [95% CI, −6% to 8%]), PD-L1–low (TPS, 1% to < 50%:

Figure 3

ORR, 8% [95% CI, −5% to 21%]), and PD-L1–high (TPS ≥
50%: ORR, 17% [95% CI, 4%-31%]) assays in the 22C3-BEP.

Inter-assay Concordance
Analyses of inter-assay concordance identified a proportion of
overlapping and uniquely positive patients between the SP142
and 22C3 assays (Figure 4 A and B and Supplemental Figure
S3). Overall, 60% (215/360) of the SP142 TC1/2/3 or IC1/2/3

Response in Assay-Deﬁned PD-L1 Subgroups.
ORRs in SP142-ITT and 22C3-BEP according to PD-L1 status determined by SP142 and 22C3 assays. Delta between
arms and corresponding 95% CI are shown.
Abbreviations: BEP = biomarker-evaluable population; IC = tumor-infiltrating immune cells; ITT = intention to treat;
ORR = objective response rate; PD-L1 = programmed death ligand 1; TC = tumor cells; TPS = tumor proportion score.
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Figure 1

OS and PFS in Overall Populations and Assay-Deﬁned PD-L1 Subgroups.
Forest plots of OS (A) and PFS (B) for atezolizumab and docetaxel in the SP142-ITT, 22C3-BEP, and non–22C3-BEP
subpopulations and by SP142- and 22C3-defined PD-L1 status in the 22C3-BEP.
∗
OS results for atezolizumab versus docetaxel in the overall and PD-L1 subgroups in the SP142-ITT population have
been previously published.11
Abbreviations: Atezo = atezolizumab; BEP = biomarker-evaluable population; doc = docetaxel; IC = tumor-infiltrating
immune cells; ITT = intention to treat; OS = overall survival; PD-L1 = programmed death ligand 1; PFS =
progression-free survival; TC = tumor cells; TPS = tumor proportion score.

subgroup was also considered PD-L1 positive (TPS ≥ 1%) according to the 22C3 assay. Among patients with high PD-L1–expressing
tumors defined by the SP142 assay (TC3 or IC3), 64% (60/94)
were also considered PD-L1 high (TPS ≥ 50%) by the 22C3 assay.
In patients with tumors that had lower levels of PD-L1 expression,
31% (82/266) of the SP142 TC1/2 or IC1/2 subgroup was also
considered PD-L1 low (TPS, 1% to < 50%) by the 22C3 assay.
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Each assay identified a unique population of patients in the
22C3-BEP who were nonoverlapping (single positive) between the
assays: 6% of the patients were defined as SP142 PD-L1 high but
were not 22C3 PD-L1 high; 25% were SP142 PD-L1 positive
but not 22C3 PD-L1 positive; 13% were 22C3 PD-L1 high but
not SP142 PD-L1 high; and 9% were 22C3 PD-L1 positive but
not SP142 PD-L1 positive (Figure 4 A and B). Of the SP142
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Figure 2

Overall Survival in Assay-Deﬁned PD-L1 Subgroups in the 22C3-BEP.
Kaplan-Meier plots of OS according to assay-defined PD-L1 subgroups within the 22C3-BEP: (A) PD-L1–high expression
defined as SP142 TC ≥ 50% or IC ≥ 10% (TC3 or IC3) or 22C3 TPS ≥ 50%; (B) PD-L1–positive expression as SP142 TC
or IC ≥ 1% (TC1/2/3 or IC1/2/3) or 22C3 TPS ≥ 1%; (C) PD-L1–low expression as SP142 TC or IC ≥ 1% and TC < 50%
and IC < 10% (TC1/2 or IC1/2) or 22C3 TPS 1% to < 50%; and (D) PD-L1–negative expression as SP142 TC and IC <
1% each (TC0 and IC0) or 22C3 TPS < 1%. OS results for atezolizumab versus docetaxel in the overall and PD-L1
subgroups in the SP142-ITT population have been previously published.11
Abbreviations: BEP = biomarker-evaluable population; IC = tumor-infiltrating immune cells; ITT = intention to treat;
OS = overall survival; PD-L1 = programmed death ligand 1; TC = tumor cells; TPS = tumor proportion score.
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Figure 4
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Analytical Concordance Between SP142 and 22C3 Assays and Treatment Effects on Clinical Outcomes
in Overlapping and Nonoverlapping PD-L1 Populations.
Venn diagrams of the overlap between assays by PD-L1 expression status according to A) SP142 TC3 or IC3 (TC ≥ 50%
or IC ≥ 10%) and 22C3 TPS ≥50% (PD-L1 high) and B) SP142 TC1/2/3 or IC1/2/3 (TC or IC ≥ 1%) and 22C3 TPS ≥ 1%;
and Forest plots of OS (C) and PFS (D) in 22C3-BEP double-selected populations according to SP142 and 22C3-defined
PD-L1 status.
Abbreviations: Atezo, atezolizumab; BEP = biomarker-evaluable population; CI = confidence interval; doc = docetaxel;
DN = double negative; DP = double positive; HR = hazard ratio; IC = tumor-infiltrating immune cells; ITT = intention
to treat; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed death ligand 1; SP = single
positive; TC = tumor cells; TPS = tumor proportion score.
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uniquely identified PD-L1–high subgroup, the majority were classified as IC3 and not TC3 (Supplemental Figure S4). Likewise, most
patients uniquely identified as having PD-L1–positive tumors by
SP142 were classified as IC1/2/3 and not TC1/2/3 (Supplemental
Figure S4). When restricting the SP142 assay scoring to TC staining only (any IC status), the 22C3 assay identified a larger proportion of patients in both the PD-L1–positive (SP142 TC1/2/3 and
22C3 TPS ≥ 1%) and the PD-L1–high (SP142 TC3 and 22C3
TPS ≥ 50%) subgroups (Supplemental Figure S5). Moreover, most
SP142 TC-only defined tumors were captured within the 22C3 TPS
population (Supplemental Figure S5).

Clinical Outcomes in SP142 and 22C3 Overlapping and
Nonoverlapping Populations
Clinical benefit within the SP142 and 22C3 overlapping and
uniquely identified subgroups were examined at the PD-L1–high
and positive cutoffs (Figures 4 C and D and 5 and Supplemental
Figure S6). Among PD-L1–high subgroups, there were OS benefits
with atezolizumab versus docetaxel in the double-positive population with tumors defined as SP142 TC3 or IC3 and 22C3 TPS
≥ 50% (difference in median OS [mOS], 14 months; HR, 0.38
[95% CI, 0.21-0.69]) and among SP142 uniquely positive patients
with tumors identified as SP142 TC3 or IC3 and 22C3 TPS
< 50% (mOS, 11.8 months; HR, 0.39 [95% CI, 0.17-0.87])
(Figures 4C and 5). Reduced OS benefit with atezolizumab versus
docetaxel was observed in the 22C3 uniquely positive population
classified as SP142 TC0/1/2 or IC0/1/2 and 22C3 TPS ≥ 50%
(mOS, 1.4 months; HR, 0.73 [95% CI, 0.43-1.25]) and doublenegative patients with tumors defined as SP142 TC0/1/2 or IC0/1/2
and 22C3 TPS < 50% (mOS, 2.6 months; HR, 0.72 [95%
CI, 0.58-0.90]). PFS benefits were observed with atezolizumab
versus docetaxel in the SP142 TC3 or IC3/22C3 TPS ≥ 50%
double-positive population and in SP142 uniquely positive (SP142
TC3 or IC3 and 22C3 TPS < 50%) and 22C3 uniquely positive
(SP142 TC0/1/2 or IC0/1/2 and 22C3 TPS ≥ 50%) populations
(Figure 4D and Supplemental Figure S6). No PFS differences were
shown between atezolizumab and docetaxel in the double-negative
PD-L1 subgroup (Figure 4D and Supplemental Figure S6).
At the PD-L1–positive cutoff, OS benefit with atezolizumab
versus docetaxel was observed in the SP142 TC1/2/3 or IC1/2/3
and 22C3 TPS ≥ 1% double-positive population (mOS, 6.6
months; HR, 0.55 [95% CI, 0.40-0.75]), 22C3 uniquely positive
patients with tumors defined as SP142 TC0 and IC0 and 22C3 TPS
≥ 1% (mOS, 7.4 months; HR, 0.63 [95% CI, 0.35-1.14]), and
double-negative patients with tumors defined as SP142 TC0 and
IC0 and 22C3 TPS < 1% (mOS, 2.2 months; HR, 0.67 [95%
CI, 0.48-0.95]) (Figures 4C and 5). Among SP142 uniquely positive
patients (with tumors classified as SP142 TC1/2/3 or IC1/2/3 and
22C3 TPS < 1%), median OS was 12.5 months in the atezolizumab
group and 8.4 months in the docetaxel group (mOS, 4.1 months),
with a HR point estimate of 0.90 (95% CI, 0.62-1.29). PFS HR
point estimates for atezolizumab versus docetaxel were 0.60 (95%
CI, 0.45-0.80) in the SP142 TC1/2/3 or IC1/2/3 and 22C3 TPS
≥ 1% double-positive population and 0.76 (95% CI, 0.43-1.35)
in 22C3 uniquely positive patients (with tumors defined as SP142
TC0 and IC0 and 22C3 TPS ≥ 1%) (Figure 4D and Supplemen-

tal Figure S6). The double-negative and SP142 uniquely positive
subgroups did not show PFS improvements with atezolizumab
compared with docetaxel (Figure 4D and Supplemental Figure S6).

Discussion
In this retrospective exploratory analysis from the OAK trial,
we compared the analytical and predictive value of the SP142 and
22C3 PD-L1 IHC assays. Despite differences in assay sensitivity and
scoring algorithms, both assays were able to predict benefit from
atezolizumab in the second-line setting in patients with NSCLC.
Survival benefit was observed for atezolizumab over docetaxel across
PD-L1 subgroups from the 22C3-BEP, including patients bearing
tumors negative for PD-L1 by both assays.
Increasingly, first-line approvals of checkpoint inhibitor
monotherapy and in combination chemotherapy are superseding their use in the second-line treatment setting. Atezolizumab
monotherapy showed clinically meaningful OS benefit over
chemotherapy in first-line NSCLC, specifically in patients
with PD-L1–high tumors (TC3 or IC3) defined by the SP142
assay.12 , 18 , 28 , 29 , 30 Likewise, pembrolizumab monotherapy showed
OS benefit over chemotherapy in NSCLC populations with PDL1–expressing tumors defined by the 22C3 assay (TPS ≥ 1 and
TPS ≥ 50%).12 , 18 , 28 , 29 As a result, PD-L1 testing is recommended
in the first-line setting.28 , 29 The finding that both the SP142
and 22C3 assays effectively predict atezolizumab benefit in these
OAK subgroup analyses of a second-line NSCLC population,
particularly among patients with tumors having PD-L1–high
expression (TC3 or IC3 or TPS ≥ 50%), is relevant for informing
current practice recommendations for PD-L1–based selection of
checkpoint inhibitor monotherapy in the first-line setting. Indeed,
while recognizing the limitations of comparing assay performance
and predictive values between all-comer patients in the second-line
setting and first-line PD-L1-selected populations, interim results
from the NSCLC phase III IMpower110 study showed an OS
benefit with first-line atezolizumab monotherapy compared with
platinum-based chemotherapy among PD-L1–high patients defined
by either the SP142, 22C3, or SP263 assays.30 Such findings are
supportive of the inter-assay clinical concordance presented here
and highlight the clinical utility of the SP142 assay in selecting for
patients deriving benefit from atezolizumab across therapy lines.
Lower sensitivity of the SP142 assay for TC and differences in
staining patterns compared with 22C3 and other PD-L1 IHC assays
has been previously established in the Blueprint studies, among
others,21 , 23 , 24 , 31 and aligns with our finding that most unique
SP142-defined populations were positive for IC and not TC. Nevertheless, despite slight differences in identified patient populations
between the SP142 and 22C3 assays (the SP142 assay will identify
a proportion of patients who are excluded by the 22C3 assay and
vice versa), the current finding of OS benefit with atezolizumab
versus docetaxel in double-positive PD-L1 subgroups implies that
both assays effectively select for patients who derive clinical benefit
with atezolizumab. Although such studies are generally lacking,
a previous report also suggests general agreement in inter-assay
biomarker predictiveness for survival outcomes with immunotherapy in NSCLC. Small sample sizes within single selected subgroups
preclude a definitive conclusion with respect to the predictiveness
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Figure 5

Overall Survival in 22C3-BEP Double-Selected Populations Deﬁned by Different PD-L1 Group
Combinations.
Kaplan-Meier plots of OS in 22C3-BEP double-selected populations defined by PD-L1–positive (A-D) or high (E-H)
status. PD-L1–positive expression status was defined as SP142 TC or IC ≥ 1% (TC1/2/3 or IC1/2/3) or TC ≥ 50% or IC ≥
10% (TC3 or IC3; PD-L1 high), or as 22C3-defined TPS ≥ 1% or ≥ 50% (PD-L1 high).
Abbreviations: BEP = biomarker-evaluable population; IC = tumor-infiltrating immune cells; OS = overall survival;
PD-L1 = programmed death ligand 1; TC = tumor cells; TPS = tumor proportion score.

of IC versus TC in this analysis and may prove misleading given
that, by detecting PD-L1 on both TC and IC, the SP142 assay
is designed to comprehensively characterize the PD-L1 status of a
given tumor.27 Indeed, analyses of NSCLC cases from atezolizumab
clinical studies have shown that, although PD-L1 expression (and
therefore anticancer immunity) is differentially regulated on TC and
IC, PD-L1 status on both TC and IC independently predicts clinical benefit from atezolizumab.30 , 32 , 33
In support of the clinical utility of an assay algorithm that
combines TC and IC scoring, the shown predictive value of the
22C3 combined positive score (TC/IC) has formed the basis for
pembrolizumab treatment in head and neck, urothelial, gastric,
esophageal, and cervical cancer as well as triple-negative breast
cancer, for which PD-L1 scoring of TC alone is not adequately
predictive.16 , 18 , 20 , 34 Similarly, IC-driven PD-L1 selection by the
SP142 assay underlies atezolizumab use in urothelial cancer and
triple-negative breast cancer.35
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Consistent with our study results, clinical trial observations
support PD-L1 as a continuous biomarker for predictiveness of
efficacy with immunotherapy in NSCLC, with greater benefit as
PD-L1 expression levels increase.36 This subanalysis also identified
a population of patients with tumors that were PD-L1 negative
by either assay who gained benefit from atezolizumab, highlighting
the need to determine additional, well-characterized biomarkers to
accurately select the likelihood of response to checkpoint inhibitors
in the absence of detectable PD-L1 levels. Blood tumor mutational
burden is a promising biomarker for selecting response to checkpoint inhibitors37 and may be of enhanced predictive value when
used in conjunction with selection for PD-L1–high expression.
Notably, an analysis of the OAK and POPLAR studies reported an
association between longer survival (PFS and OS) and high and low
blood tumor mutational burden in PD-L1–high subgroups receiving atezolizumab.38 Additional clinical trials, as well as utilizing
novel analyses both retrospectively and prospectively, are needed to
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characterize and combine new biomarkers with PD-L1 status to
more accurately identify patients who would benefit from checkpoint inhibitors.
Greater survival benefits with atezolizumab versus docetaxel in
22C3-BEP relative to non–22C3-BEP is a potential limitation of
the current retrospective, exploratory analysis, and results should be
interpreted with caution. This appears to be the result of docetaxel
overperformance in the non–22C3-BEP and may be attributed to
differences in baseline prognostic factors, such as lower sum of
longest diameters or demographic disparities. Only patients with
available tissue blocks or slides within the 6-month cut slide–
stability window were included in the 22C3-BEP; therefore, there
was a significantly lower number of Asian patients. Asian countries
are more likely to provide slides at enrollment instead of tissue
blocks, likely resulting in time differences in cut slide stability and
a lack of available tissue. Balanced proportions of Asian patients
between arms and association of Asian ethnicity with a favorable
disease prognosis39 preclude a lower frequency of Asian patients as a
reason for improved survival in 22C3-BEP versus non–22C3-BEP
and SP142-ITT populations. It should be noted that the prevalence rates for the 22C3-defined PD-L1–positive subgroup (47%)
were slightly lower than previously reported in the published literature (22C3 TPS ≥ 1% PD-L1 prevalence is approximately 57% of
the ITT population26 , 40 ). This is unlikely to be explained by pre–
cut slide–stability issues and epitope deterioration because samples
in this study were stored and prepared in line with manufacturer
instructions for the 22C3 assay.

Conclusion
This current analysis from OAK provides further support that,
although each assay has a different scoring algorithm and differing levels of sensitivity, both SP142 and 22C3 assays are predictive for atezolizumab benefit at validated PD-L1 expression thresholds in patients with NSCLC. Moreover, the observed results verify
the atezolizumab all-comer benefit observed in the second-line or
higher NSCLC setting and inform the changing landscape of PDL1–selected treatment in the first-line setting.

Clinical Practice Points
•

•

•

•

The phase III OAK trial previously showed greater survival
with atezolizumab than the historical standard-of-care treatment, docetaxel, in a population of patients with metastatic
NSCLC receiving second- or third-line treatment regardless
of tumor PD-L1 status by the VENTANA SP142 IHC assay.
To extend knowledge on the comparative clinical sensitivities of IHC assays, this analysis of the OAK trial evaluated
the SP142 and Dako 22C3 IHC assays at established PD-L1
cutoffs.
Our results showed survival benefits with atezolizumab versus
docetaxel across PD-L1–positive and negative subgroups
from the 22C3-BEP.
Overall, despite different scoring algorithms and clinical
sensitivities, the SP142 and 22C3 assays similarly predict for
atezolizumab efficacy at validated PD-L1 expression levels in
patients with NSCLC.

•

As well as confirming the all-comer benefit of atezolizumab
in second-line or higher NSCLC, our findings may be of
value for PD-L1–defined treatment selection in the first-line
setting.
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